Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

4 articles from the last 30 days matching "Orphan Drug"

ResearchPUBMED3 days ago

Access to orphan drugs in adults with inherited metabolic diseases in Switzerland: a single-center retrospective cohort study.

Researchers in Switzerland studied how many adults with inherited metabolic diseases (rare conditions where the body cannot break down certain substances properly) were able to get orphan drugs (special medicines made for rare diseases). They looked at records from 2017 to 2022 to understand which patients received these medicines, how long it took to get them approved and paid for, and what rules made it easier or harder to access them.

WHY IT MATTERSIf you have an inherited metabolic disease in Switzerland or Europe, this study shows real-world timelines for how long it typically takes to get orphan drug approval and reimbursement—information that can help you advocate for faster access with your doctor and insurance company.
ℹ Good to know
PipelineRSSMay 5

European regulators back new DMD gene therapy with key status

European regulators have approved a special status for SGT-003, a new gene therapy treatment for Duchenne muscular dystrophy (DMD), a serious muscle disease that affects boys. This approval, called orphan drug designation, means the treatment is recognized as addressing a rare disease with few other options. The therapy is designed to help preserve muscle strength in boys with DMD.

WHY IT MATTERSSGT-003 now has regulatory backing in both the U.S. and Europe, which accelerates its development pathway and may bring a new treatment option closer to boys with DMD who currently have limited gene therapy choices.
💬 Ask your doctorDuchenne muscular dystrophy
ResearchPUBMEDMay 1

Patent Analysis Perspectives on China's Orphan Drug R&D: Status and Technology Characteristics.

Researchers studied patent applications from China between 1995 and 2023 to understand how many new orphan drugs (medicines for rare diseases) are being developed there. They found that China filed 58% more patent applications for rare disease treatments between 2018 and 2023, with most focus on cancer and brain diseases. This shows China is investing more in rare disease research, especially after new government policies were put in place.

WHY IT MATTERSPatients with rare diseases in China and globally benefit when more countries invest in orphan drug development, as increased competition and innovation can lead to more treatment options and potentially lower costs.
ℹ Good to know
ResearchPUBMEDMay 1

Analysis of Real-World Data Utilization in the Orphan Drug Approval Process: Focusing on New Drug Marketing Applications Submitted to the FDA.

Researchers looked at how the FDA approves medicines for rare diseases from 2020 to 2024. They found that 129 rare disease drugs were approved during this time, and 25 of them (about 19%) used real-world data—information collected from patients outside of traditional clinical trials. Real-world data is becoming more important for rare diseases because it's often impossible to run large traditional studies when so few people have a disease.

WHY IT MATTERSIf you have a rare disease, this research shows the FDA is increasingly accepting real-world evidence from patient experiences and medical records to approve new treatments, which could mean faster access to medicines when traditional large-scale trials aren't feasible.
ℹ Good to know

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases